VILLA

Age-related Macular Degeneration // Clinical Trials // Michael Altaweel // Oct 07 2022

A Prospective, Observational, Post-Marketing Surveillance Study to Monitor the Safety of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration (VILLA)

  • Sponsor: Genentech, Inc.
  • Principal Investigator: Michael Altaweel, MD
  • Study Coordinator: Kris Dietzman

Study objective:

To evaluate safety and tolerability of the Port Delivery System (PDS) in patients with neovascular age-related macular degeneration (nAMD).

Study design:

Patients planned to receive a PDS implant for treatment of nAMD will be followed for a fixed period of 3 years after initial implantation. This is a prospective, single-arm, observational study.

Inclusion criteria:

  • Diagnosis of nAMD
  • Clinical decision has been made for the treatment with the PDS

Exclusion criteria:

  • Active participation in any other clinical trial for nAMD
  • Active participation in any other medical or surgical interventional ophthalmology clinical trial
  • Patients who have already received PDS treatment before study entry

Contact Kris Dietzman with questions: 608-263-9035.